Eveline R. Y. Scheerders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eveline R. Y. Scheerders has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Renate Ruth van Den Bos
Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center , Rotterdam
4 shared publications - Tamar Nijsten
Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
3 shared publications Marie Josee E. van Rijn
Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publicationsWendy S.J. Malskat
Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands
2 shared publicationsCatherine van Montfrans
Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands
1 shared publication- Catherine van Montfrans
Department of Dermatology Erasmus Medical Center Rotterdam The Netherlands
1 shared publication
Latest Publications
- Open Access
- 15 August 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (2) , 307-315
Prevalence and Risk Factors of Chronic Venous Disease in a General Population in The Netherlands: Results from the Rotterdam Study
- 15 August 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (2) , 307-315
Open AccessPrevalence and Risk Factors of Chronic Venous Disease in a General Population in The Netherlands: Results from the Rotterdam Study
- Open Access
- 6 May 2024
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 68 (3) , 387-394
Development and External Validation of a Prediction Model for Patients with Varicose Veins Suitable for Isolated Ambulatory Phlebectomy
- 6 May 2024
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 68 (3) , 387-394
Open AccessDevelopment and External Validation of a Prediction Model for Patients with Varicose Veins Suitable for Isolated Ambulatory Phlebectomy
- Open Access
- 21 February 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (6) , 733
Author response to: Comment on: A randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Dear Editor
- 21 February 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (6) , 733
Open AccessAuthor response to: Comment on: A randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Dear Editor
- Open Access
- 5 December 2022
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (3) , 333-342
A randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Background: Current treatment of patients with saphenous trunk and tributary incompetence consists of truncal ablation with concomitant, delayed or no treatment of the tributary. However, reflux of the saphenous trunk may be reversible after treatment of the incompetent tributary. The aim of this study was to determine whether single ambulatory phlebectomy with or without delayed endovenous truncal ablation (SAP) is non-inferior to thermal endovenous ablation with concomitant phlebectomy (TAP), and whether SAP is a cost-effective alternative to TAP. Methods: A multicentre, non-inferiority RCT was conducted in patients with an incompetent great saphenous vein or anterior accessory saphenous vein with one or more incompetent tributaries. Participants were randomized to receive SAP or TAP. After 9 months, additional truncal treatment was considered for SAP patients with remaining symptoms. The primary outcome was VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Symptoms (VEINES-QOL/Sym score) after 12 months. Secondary outcomes were, among others, cost-effectiveness, perceived improvement of symptoms, and anatomical success. Results: Some 464 patients received the allocated treatment (SAP 227, TAP 237). VEINES-QOL scores were 52.7 (95 per cent c.i. 51.9 to 53.9) for SAP and 53.8 (53.3 to 55.1) for TAP; VEINES-Sym scores were 53.5 (52.6 to 54.4) and 54.2 (54.0 to 55.6) respectively. Fifty-eight patients (25.6 per cent) in the SAP group received additional truncal ablation. Treatment with SAP was less costly than treatment with TAP. Conclusion: One year after treatment, participants who underwent SAP had non-inferior health-related quality of life compared with those who had TAP. Treatment with SAP was a cost-effective alternative to TAP at 12 months. Registration number: NTR 4821 (www.trialregister.nl).
- 5 December 2022
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (3) , 333-342
Open AccessA randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Background: Current treatment of patients with saphenous trunk and tributary incompetence consists of truncal ablation with concomitant, delayed or no treatment of the tributary. However, reflux of the saphenous trunk may be reversible after treatment of the incompetent tributary. The aim of this study was to determine whether single ambulatory phlebectomy with or without delayed endovenous truncal ablation (SAP) is non-inferior to thermal endovenous ablation with concomitant phlebectomy (TAP), and whether SAP is a cost-effective alternative to TAP. Methods: A multicentre, non-inferiority RCT was conducted in patients with an incompetent great saphenous vein or anterior accessory saphenous vein with one or more incompetent tributaries. Participants were randomized to receive SAP or TAP. After 9 months, additional truncal treatment was considered for SAP patients with remaining symptoms. The primary outcome was VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Symptoms (VEINES-QOL/Sym score) after 12 months. Secondary outcomes were, among others, cost-effectiveness, perceived improvement of symptoms, and anatomical success. Results: Some 464 patients received the allocated treatment (SAP 227, TAP 237). VEINES-QOL scores were 52.7 (95 per cent c.i. 51.9 to 53.9) for SAP and 53.8 (53.3 to 55.1) for TAP; VEINES-Sym scores were 53.5 (52.6 to 54.4) and 54.2 (54.0 to 55.6) respectively. Fifty-eight patients (25.6 per cent) in the SAP group received additional truncal ablation. Treatment with SAP was less costly than treatment with TAP. Conclusion: One year after treatment, participants who underwent SAP had non-inferior health-related quality of life compared with those who had TAP. Treatment with SAP was a cost-effective alternative to TAP at 12 months. Registration number: NTR 4821 (www.trialregister.nl).
- Open Access
- 14 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (2) , 428-435
A prospective, multicentre study to assess frailty in elderly patients with leg ulcers (GERASstudy)
Background: Although leg ulcers are a burdensome disease most common in those aged 65 years and older, frailty in this population has not yet been well established.Objectives: The aim of this study was to prospectively explore and compare the presence of frailty in elderly patients with chronic leg or foot ulcers by applying different validated frailty screening methods in three healthcare settings and to assess the feasibility of frailty screening.Methods: We compared frailty of leg ulcer patients referred to an academic hospital with a non‐academic hospital, leg ulcer patients receiving (primary) homecare, and a dermato‐oncology patient population (control group). Frailty and quality of life were assessed using four validated questionnaires: the Groninger Frailty Indicator, Geriatric‐8, Mini‐Cog and Wound Quality of Life. To analyse data multiple (non)‐parametric tests were performed.Results: Fifty of 60 included leg ulcer patients (83%) scored “frail” on at least one frailty questionnaire (GFI, G8 or Mini‐Cog). The number of patients scoring “frail” on two or three out of three applied frailty questionnaires were significantly higher in the academic and homecare ulcer population compared with the non‐academic ulcer population and control group (p = 0.002). In the academic ulcer population mean Wound Quality of Life scores were 30.2 (SD 17.6), compared with 17.7 (SD 13.1) in the non‐academic and 15.0 (SD 10.4) in the homecare ulcer population (p = 0.002).Conclusion: The majority of patients suffering from leg ulcers in this study was frail. The highest frailty prevalence was observed in the academic and homecare ulcer populations. The largest impaired quality of life was reported in the academic ulcer population. In dermatology practice, implementing frailty screening and initiating appropriate (paramedical) supportive care should be considered to improve patient outcomes.
- 14 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (2) , 428-435
Open AccessA prospective, multicentre study to assess frailty in elderly patients with leg ulcers (GERASstudy)
Background: Although leg ulcers are a burdensome disease most common in those aged 65 years and older, frailty in this population has not yet been well established.Objectives: The aim of this study was to prospectively explore and compare the presence of frailty in elderly patients with chronic leg or foot ulcers by applying different validated frailty screening methods in three healthcare settings and to assess the feasibility of frailty screening.Methods: We compared frailty of leg ulcer patients referred to an academic hospital with a non‐academic hospital, leg ulcer patients receiving (primary) homecare, and a dermato‐oncology patient population (control group). Frailty and quality of life were assessed using four validated questionnaires: the Groninger Frailty Indicator, Geriatric‐8, Mini‐Cog and Wound Quality of Life. To analyse data multiple (non)‐parametric tests were performed.Results: Fifty of 60 included leg ulcer patients (83%) scored “frail” on at least one frailty questionnaire (GFI, G8 or Mini‐Cog). The number of patients scoring “frail” on two or three out of three applied frailty questionnaires were significantly higher in the academic and homecare ulcer population compared with the non‐academic ulcer population and control group (p = 0.002). In the academic ulcer population mean Wound Quality of Life scores were 30.2 (SD 17.6), compared with 17.7 (SD 13.1) in the non‐academic and 15.0 (SD 10.4) in the homecare ulcer population (p = 0.002).Conclusion: The majority of patients suffering from leg ulcers in this study was frail. The highest frailty prevalence was observed in the academic and homecare ulcer populations. The largest impaired quality of life was reported in the academic ulcer population. In dermatology practice, implementing frailty screening and initiating appropriate (paramedical) supportive care should be considered to improve patient outcomes.